These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35471500)

  • 1. Bringing mass spectrometry into the care of patients with multiple myeloma.
    Murray DL
    Int J Hematol; 2022 Jun; 115(6):790-798. PubMed ID: 35471500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
    Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
    Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
    Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
    Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
    Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
    Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
    Chapman JR; Thoren KL
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101142. PubMed ID: 32139008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
    Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
    Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
    Guan L; Su W; Zhong J; Qiu L
    Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearing drug interferences in myeloma treatment using mass spectrometry.
    Kohlhagen MC; Mills JR; Willrich MAV; Dasari S; Dispenzieri A; Murray DL
    Clin Biochem; 2021 Jun; 92():61-66. PubMed ID: 33691184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
    Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
    J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.
    Barnidge DR; Dasari S; Botz CM; Murray DH; Snyder MR; Katzmann JA; Dispenzieri A; Murray DL
    J Proteome Res; 2014 Mar; 13(3):1419-27. PubMed ID: 24467232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis.
    Murray DL; Dasari S
    Clin Lab Med; 2021 Jun; 41(2):203-219. PubMed ID: 34020760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
    Thoren KL
    Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.
    Abeykoon JP; Murray DL; Murray I; Jevremovic D; Otteson GE; Dispenzieri A; Arendt BK; Dasari S; Gertz M; Gonsalves WI; Kourelis TV; Muchtar E; Dingli D; Warsame R; Go RS; Lacy MQ; Leung N; Buadi F; Lin Y; Kyle RA; Rajkumar V; Kumar S; Kapoor P
    Br J Haematol; 2021 Apr; 193(2):380-385. PubMed ID: 33216966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
    Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
    Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma.
    Long S; Qin Q; Wang Y; Yang Y; Wang Y; Deng A; Qiao L; Liu B
    Talanta; 2019 Aug; 200():288-292. PubMed ID: 31036186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab.
    Kohlhagen M; Dasari S; Willrich M; Hetrick M; Netzel B; Dispenzieri A; Murray DL
    Clin Chem Lab Med; 2020 Aug; 59(1):155-163. PubMed ID: 32745067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Analysis of Peptides.
    Sandoval W
    Curr Protoc Protein Sci; 2014 Aug; 77():16.2.1-16.2.11. PubMed ID: 25081740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.